Viking Therapeutics Advances Weight-Loss Drug Program with Key Clinical Updates
02.02.2026 - 05:47:04
Viking Therapeutics has released new clinical data for its investigational drug VK2735, providing fresh insight into the candidate's potential in the competitive obesity therapeutics market. The company also reported progress across its broader development pipeline and strengthened its executive team with a new commercial lead.
The biopharmaceutical firm's near-term calendar features several important milestones. Investors are anticipating the next quarterly financial report, scheduled for February 10. Furthermore, the company is preparing to advance its pivotal Phase 3 program, with the VANQUISH-2 trial focusing on patients with type 2 diabetes expected to complete enrollment in the first quarter.
Detailed Phase 2 Data Published in Medical Journal
Newly published results from the Phase 2 VENTURE study are currently drawing significant attention. The data, featured in the peer-reviewed journal Obesity, detail the performance of VK2735, a dual GLP-1 and GIP receptor agonist.
After a 13-week treatment period, participants experienced an average reduction in body weight of up to 14.7% from their baseline. A notable observation from the published findings was that the rate of weight loss showed no signs of plateauing during the study's duration.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Expansion of Clinical Trials and Executive Leadership
Alongside these results, Viking recently completed patient recruitment for a separate maintenance dosing study. This trial is designed to evaluate various regimens, including monthly and weekly administration schedules, for sustaining weight reduction. The study will assess both subcutaneous and oral formulations of the drug.
The cornerstone of the development strategy remains the VANQUISH Phase 3 program for the subcutaneous version of VK2735. Enrollment for the VANQUISH-1 trial, involving approximately 4,650 participants, was finalized in November. The parallel VANQUISH-2 study will follow as noted.
In a corporate development, Viking Therapeutics appointed Neil Aubuchon as its Chief Commercial Officer earlier this month. The company stated this move brings extensive global commercialization and marketing expertise to its leadership team.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from February 2 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 2.
Viking Therapeutics: Buy or sell? Read more here...
